ScholarLens Back to search
1989•Archives of DermatologyRequires access

A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporis

G. W. Cole

Open publisher page 5 citations

Abstract

• Fifty patients with tinea corporis were treated with either 500 mg of griseofulvin (microsize) or 500 mg of terbinafine daily for 6 weeks. Thirty-three patients completed the study. Thirteen (87%) of 15 patients who took terbinafine were considered successfully treated, while 13 (73%) of 18 patients in the griseofulvin group noted resolution of their disease. Five patients taking griseofulvin were forced to discontinue the therapy because of side effects, compared with two patients taking terbinafine. This preliminary study indicates that a new oral antifungal agent of the allylamine class, terbinafine, may possess a safety and efficacy profile similar to that of griseofulvin. (Arch Dermatol. 1989;125:1537-1539)

About this research paper

What this paper is about

• Fifty patients with tinea corporis were treated with either 500 mg of griseofulvin (microsize) or 500 mg of terbinafine daily for 6 weeks. Thirty-three patients completed the study. Thirteen (87%) of 15 patients who took terbinafine were considered successfully treated, while 13 (73%) of 18 patients in the griseofulvin group noted resolution of their disease. Five patients taking griseofulvin were forced to discontinue the therapy because of side effects, compared with two patients taking terbinafine. This preliminary study indicates that a new oral antifungal agent of the allylamine class, terbinafine, may possess a safety and efficacy profile similar to that of griseofulvin. (Arch Dermatol. 1989;125:1537-1539)

Why it matters

OpenAlex reports 5 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

• Fifty patients with tinea corporis were treated with either 500 mg of griseofulvin (microsize) or 500 mg of terbinafine daily for 6 weeks. Thirty-three patients completed the study. Thirteen (87%) of 15 patients who took terbinafine were considered successfully treated, while 13 (73%) of 18 patients in the griseofulvin group noted resolution of their disease. Five patients taking griseofulvin were forced to discontinue the therapy because of side effects, compared with two patients taking terbinafine. This preliminary study indicates that a new oral antifungal agent of the allylamine class, terbinafine, may possess a safety and efficacy profile similar to that of griseofulvin. (Arch Dermatol. 1989;125:1537-1539)

Key concepts: Terbinafine, Griseofulvin, Tinea capitis, Medicine, Dermatology, Antifungal, Mycosis, Allylamine

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporis — Research Paper | ScholarLens